SCHEMBL615299

SCHEMBL615299

CCN(CCOC)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.56
MAOB P27338 5/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
LTA4H P09960 1/20 0.50
HTT P42858 1/20 0.50
MAOA P21397 1/20 0.49
KDM4E B2RXH2 2/20 0.49
CNR2 P34972 1/20 0.49
BCHE P06276 4/20 0.47
DRD1 P21728 2/20 0.47
DRD3 P35462 2/20 0.47
DRD2 P14416 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CHRM2 P08172 1/20 0.47
HTR1A P08908 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8281044 0.90 MEN1 (0.51) TSHRMAPK1CYP1A2CYP2D6CYP2C9
SCHEMBL8281042 0.90 MEN1 (0.51) TSHRMAPK1CYP1A2CYP2D6CYP2C9
SCHEMBL614958 0.84 TSHR (0.50) TSHRMAPK1MAOBCYP1A2CYP2D6
SCHEMBL9504529 0.84 MEN1 (0.48) TSHRMAPK1CYP1A2CYP2D6CYP2C9
SCHEMBL14019814 0.84 MEN1 (0.51) MEN1KMT2A
SCHEMBL9635924 0.83 KDM4E (0.47) TSHRMAPK1MAOBCYP1A2CYP2D6
SCHEMBL17230510 0.82 TSHR (0.49) TSHRMAPK1
SCHEMBL3620117 0.82 KDM4E (0.56) KDM4EMEN1KMT2A
SCHEMBL14376647 0.82 MCHR1 (0.46) MEN1KMT2A
Hydrochloric Acid SCHEMBL8986048 0.82 MEN1 (0.47) TSHRMAPK1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
US-8466287-B2 Process for producing tricyclic ketone KABUSHIKI KAISHA YAKULT HONSHA (JP) 2013-06-18 US disclosed
US-20120041204-A1 PROCESS FOR PRODUCING TRICYCLIC KETONE KABUSHIKI KAISHA YAKULT HONSHA (JP) 2012-02-16 US disclosed
US-8067595-B2 Process for producing tricyclic ketone KABUSHIKI KAISHA YAKULT HONSHA (JP) 2011-11-29 US disclosed
US-20090023927-A1 Process for producing tricyclic ketone KABUSHIKI KAISHA YAKULT HONSHA (JP) 2009-01-22 US disclosed
EP-1900740-A1 PROCESS FOR PRODUCING TRICYCLIC KETONE Kabushiki Kaisha Yakult Honsha (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041204-A1 PROCESS FOR PRODUCING TRICYCLIC KETONE TKT, DCK, COASY TSHR 3783/4885MAPK1 3286/4885MAOB 2433/4885
US-20090023927-A1 Process for producing tricyclic ketone TKT, DCK, COASY TSHR 3783/4885MAPK1 3286/4885MAOB 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.